Processa Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Supplementary Financial Information (unaudited)

Supplementary Financial Information (unaudited)

12 Months Ended

Dec. 31, 2014

Notes

Supplementary Financial Information (unaudited)

13. SUPPLEMENTARY FINANCIAL INFORMATION (UNAUDITED)

The following summarizes the Companys quarterly results of operations for 2014 and 2013:

2014	March 31		June 30		September 30		December 31
Total revenue	$	20,345	$	112,835	$	52,621	$	14,400
Net loss		(1,344,276)		(851,216)		(791,954)		(1,538,804)
Net loss applicable to common stockholders		(1,382,824)		(912,351)		(871,840)		(2,862,126)
Net loss per common share basic and diluted	$	(0.17)	$	(0.11)	$	(0.10)	$	(0.32)

2013	March 31		June 30		September 30		December 31
Total revenue	$	19,200	$	97,280	$	125,910	$	70,090
Net loss		(816,365)		(726,571)		(718,840)		(806,925)
Net loss applicable to common stockholders		(915,307)		(768,358)		(932,600)		(473,738)
Net loss per common share basic and diluted	$	(0.48)	$	(0.34)	$	(0.12)	$	(0.06)

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References + Details